PSI

This week's FierceBiotech is brought to you by PSI.

“This is one of the most seamless partnerships between a sponsor and a CRO that I have ever seen.”

- from the development team that brought Abraxane™ to the market

Watch Sergio Cantoreggi, PhD, Head R&D of Helsinn, discuss PSI’s performance on their pivotal CINV Pediatric Oncology Program

Contact PSI today for your Oncology trial

Our Therapeutic Excellence

PSI has generated data for break-through products in Breast Cancer, CINV (adult and pediatric), Advanced Prostate Cancer, Multiple Myeloma, CIN, NHL achieving unprecedented adherence to planned program timelines.

5,600+

oncology treatment centers in

50+ countries

Dozens of FDA and EMA inspections to PSI sites resulting in drug approvals in:

■	Breast Cancer
■	NSCLC
■	Pancreatic Cancer
■	Chemotherapy-Induced Neutropenia
■	Advanced Prostate Cancer
■	CINV
■	Multiple Myeloma

View case studies

Connect

Connect with PSI on our social networks to keep up to date with the latest news from around the globe.

Want to reach 148,000+ FierceBiotech subscribers with your own message?
Contact jfordi@fiercemarkets.comor call 202-824-5041.

About this email: In order to receive FierceBiotech for free, we ask that you accept an occasional email promotion from our sponsors. We carefully screen each promotion and never sell or give away your personal information. If you do not want to receive these messages, you can unsubscribe entirely from FierceBiotech.
Click here to unsubscribe.

FierceMarkets 1900 L St. NW Suite we 400 Washington, DC 20036